Top Markets
Coin of the day
Kazia Therapeutics Limited Kazia Therapeutics Limited

Kazia Therapeutics Limited

KZA
Rangering i aksjer #35840
Kazia Therapeutics Limited is a biotechnology firm specializing in oncology,... Kazia Therapeutics Limited is a biotechnology firm specializing in oncology, committed to developing innovative therapies for cancer. Its flagship product candidate, Paxalisib, is a brain-penetrant small molecule that inhibits the PI3K/Akt/mTor pathway and is currently being investigated as a potential treatment for glioblastoma. Additionally, the company is progressing EVT801, an investigational new drug aimed at combating various types of cancer. Established in 1994 and headquartered in Sydney, Australia, the entity was formerly known as Novogen Limited before adopting the name Kazia Therapeutics Limited in November 2017.
Aksjekurs
$0.05207079
Sist synkronisert: 2023-11-15
Markedsverdi
$3.38M
Endring (1 dag)
0.13%
Endring (1 år)
0.00%
Land
AU
Handel Kazia Therapeutics Limited (KZA)

Kategori

P/B-forhold for Kazia Therapeutics Limited (KZA)
P/B-forhold per 2026 TTM: 0
Ifølge Kazia Therapeutics Limited sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for Kazia Therapeutics Limited fra 2026 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
Ikke nok data for de angitte datoene.
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
6.3419 -
US
6.2413 -
NL
- -
CH
- -
KR
3.4612 -
BE